Cancer biotech Cerulean files for a $75 million IPO

By Renaissance Capital,

Shutterstock photo

Cerulean Pharma, a clinical-stage biotech developing targeted cancer therapies for liver and ovarian cancer, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol CERU. Cerulean initially filed confidentially on January 30, 2014. Leerink Partners is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: CERU

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by